Jefferies Financial Group Initiates Coverage on Medline (NASDAQ:MDLN)

Jefferies Financial Group began coverage on shares of Medline (NASDAQ:MDLN) in a report issued on Monday. The brokerage set a “buy” rating and a $50.00 price target on the stock. Jefferies Financial Group’s price target points to a potential upside of 23.40% from the stock’s current price.

A number of other research analysts have also recently weighed in on MDLN. William Blair assumed coverage on shares of Medline in a research note on Monday. They issued an “outperform” rating on the stock. Mizuho assumed coverage on Medline in a research note on Monday. They issued an “outperform” rating and a $48.00 price objective on the stock. JPMorgan Chase & Co. assumed coverage on Medline in a research report on Monday. They issued an “overweight” rating and a $50.00 target price for the company. Leerink Partners began coverage on Medline in a research note on Monday. They issued an “outperform” rating and a $48.00 target price on the stock. Finally, Rothschild & Co Redburn initiated coverage on Medline in a research report on Monday. They set a “neutral” rating and a $42.00 price target on the stock. Twenty-one analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, Medline has a consensus rating of “Moderate Buy” and an average price target of $47.26.

Medline Stock Down 1.8%

NASDAQ MDLN opened at $40.52 on Monday. Medline has a one year low of $34.89 and a one year high of $45.50.

Insider Activity at Medline

In other Medline news, major shareholder Hellman & Friedman Capital Par sold 6,088,371 shares of the business’s stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $28.37, for a total transaction of $172,727,085.27. Following the sale, the insider owned 4,806,160 shares of the company’s stock, valued at $136,350,759.20. The trade was a 55.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Andrew J. Mills bought 2,586,206 shares of the company’s stock in a transaction on Thursday, December 18th. The shares were bought at an average price of $29.00 per share, for a total transaction of $74,999,974.00. Following the transaction, the director owned 2,586,206 shares of the company’s stock, valued at approximately $74,999,974. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing.

More Medline News

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Jefferies started coverage with a “Buy,” highlighting Medline’s ~$25 billion supply-chain scale as a durable competitive advantage that supports growth and margin expansion. Medline’s $25 bln supply chain scale wins Jefferies “buy” in coverage debut
• Positive Sentiment: TipRanks coverage of new sell‑side initiations (e.g., J.P. Morgan) emphasizes Medline’s prime‑vendor position, branded mix shift and margin expansion runway — factors analysts say justify a premium valuation. Medline, Inc. Class A: Prime Vendor Wins, Branded Mix Shift, and Margin Expansion Support Buy Rating and Premium Valuation
• Positive Sentiment: Multiple outlets report a broad set of bullish analyst initiations after the IPO (Buy/Overweight ratings and constructive price targets), which is amplifying positive sentiment and buying interest. Analysts initiate Medline with bullish ratings after blockbuster IPO
• Positive Sentiment: Media and TV coverage — including praise from commentators such as Jim Cramer — is raising retail and institutional visibility for MDLN, supporting near‑term momentum. Jim Cramer Medline: “It’s a Terrific Company”
• Neutral Sentiment: A valuation note points out shares are trading near a DCF estimate after the recent moves, suggesting limited near‑term upside unless execution or margin beats occur — a reminder that much of the positive view is already priced in. Medline (MDLN) Valuation Check As Shares Trade Near DCF Estimate After Recent Moves

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.